Report forecast the global short bowel
syndrome (SBS) market to grow at a CAGR of 25.53% during the period 2017-2021.
Short bowel syndrome (SBS) is a metabolic
disorder occurs when the portion of the small intestine is not functioning or
removed through surgery due to digestive illness. SBS is caused by lack of
function of the small intestine. This results in malabsorption, diarrhea,
steatorrhea, fluid and electrolyte disturbances, and malnutrition. Based on
drug class, the market is segmented into GLP-2, growth hormone, glutamine, and
others.
The report covers the present scenario and
the growth prospects of the global short bowel syndrome (SBS) market for
2017-2021. To calculate the market size, the report considers the sales of the
drugs and related nutraceutical products.
The
market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
According to the report, one of the major
drivers for this market is special drug designations. As the market is
dominated by a few drugs and the pipeline also demonstrates the same, the
special designation will provide more opportunity for revenue generation and to
expand geographically. These designations carry benefits such as an extension
of patent exclusivity period to address the need for an orphan drug, tax
credits of up to 50% of R&D costs, and orphan drug’s sponsors are exempted
from paying the US FDA application fees. These benefits will reduce the burden
from vendors to develop a product for a rare disease.
Further, the report states that one of the
major factors hindering the growth of this market is severe side effects of the
drugs. The side effects involved in the use of GATTEX may hinder the adoption
rates. GATTEX is a GLP-2 analog used for the treatment of adult patients with
SBS who are dependent on parenteral support. There is an increased risk that
abnormal cells could become cancer. The few other side effects associated with
GATTEX is swelling (inflammation) or blockage in gallbladder or pancreas or
fluid overload. These side effects could lead to trouble in having a bowel
movement or passing gas, stomach area (abdomen) pain or swelling, nausea,
vomiting, swelling, and blockage in stoma opening.
Global
Short Bowel Syndrome (SBS) Market 2017-2021, has
been prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the market landscape and its growth prospects over
the coming years. The report also includes a discussion of the key vendors
operating in this market.
key players in the global short bowel
syndrome (SBS) market: Emmaus Medical, Merck, and Shire.
Other Prominent Vendors in the market are:
Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and
Zealand Pharma.
Market
driver
- Special drug designations
- For a full, detailed list, view our report
Market
challenge
- Severe side effects of the drugs
- For a full, detailed list, view our report
Market
trend
- Increased awareness of GI disorders
- For a full, detailed list, view our report
Key
questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Spanning over 70 pages “Global
Short Bowel Syndrome (SBS) Market 2017 - 2021” report covers Executive
summary, Scope of the report, Research Methodology, Introduction, Market
landscape, Orphan drug designation, Pipeline landscape, Market segmentation by
route of administration (ROA), Market segmentation by drug class, Geographical
segmentation, Decision framework, Drivers and challenges, Market trends, Vendor
landscape, Key vendor analysis, Appendix.
Please visit this link for more details: http://mrr.cm/UdK
For related reports please visit: BowelSyndrome Market Research Reports
Find all Pharma
and Healthcare Reports
at: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.